1. In Vivo
  2. >>Business Strategy

Quest Diagnostics Buys SmithKline Clinical Labs

Quest Diagnostics' agreement in February to buy SmithKline Beecham Clinical Labs for $1.3 billion in cash and stock brings together two of the three largest clinical labs in the country and makes Quest the largest reference laboratory in the country. Quest hopes to expand its national presence, better manage costs, capitalize on both companies' information expertise and bring a measure of pricing stability to a besieged industry. SmithKline wants to concentrate on its drug R&D.

Quest Diagnostics Inc. 's agreement last month to buy SmithKline Beecham Clinical Laboratories(SBCL) for $1.3 billion in cash and stock [See Deal] brings together two laboratory giants and makes Quest the nation's largest clinical reference laboratory. With more than $3 billion in sales, it will be double the size of its nearest competitor, Laboratory Corporation of America (LCA).

Quest will pay SmithKline Beecham , owner of SBCL, $1 billion in cash and give SB a 29.5% equity stake in the laboratory company. In addition, SB gets two...

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.